Current diagnosis and management of hypertensive emergency

Seminars in Dialysis

Volumn 19, Issue 6, 2006, Pages 502-512

  Haas, Andrew R ^a   Marik, Paul E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLEVIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PYRIDINE DERIVATIVE; VASODILATOR AGENT;

AORTA ANEURYSM; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; DISSECTING ANEURYSM; DRUG EFFECT; EMERGENCY TREATMENT; FEMALE; HUMAN; HYPERTENSION; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; PREGNANCY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANEURYSM, DISSECTING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AORTIC ANEURYSM; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; EMERGENCY TREATMENT; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY; PYRIDINES; VASODILATOR AGENTS;

EID: 33750938809     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00213.x     Document Type: Review

References (147)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
2. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290:199-206, 2003
3. Cherney D, Straus S: Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 17:937-945, 2002
4. Patel HP, Mitsnefes M: Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 17:210-214, 2005
5. Migneco A, Ojetti V, De LA, Silveri NG, Savi L: Hypertensive crises: diagnosis and management in the emergency room. Eur Rev Med Pharm Sci 8:143-152, 2004
6. Calhoun DA, Oparil S: Treatment of hypertensive crisis. N Engl J Med 323:1177-1183, 1990
7. Ferguson RK, Vlasses PH: Hypertensive emergencies and urgencies. JAMA 255:1607-1613, 1986
8. Reuler JB, Magarian GJ: Hypertensive emergencies and urgencies: definition, recognition, and management. J Gen Intern Med 3:64-74, 1988
9. Bertel O, Marx BE: Hypertensive emergencies. Nephron 47(Suppl. 1):51-56, 1987
10. Rahn KH: How should we treat a hypertensive emergency? Am J Cardiol 63:48C-50C, 1989
11. Kaplan NM: Treatment of hypertensive emergencies and urgencies. Heart Dis Stroke 1:373-378, 1992
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
13. The sixth report of the Joint National Committee of prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
14. Pender JR, Pories WJ: Epidemiology of obesity in the United States. Gastroenterol Clin North Am 34:1-7, 2005
15. Webber LS, Bedimo-Rung AL: The obesity epidemic: incidence and prevalence. J Lo State Med Soc 157(Spec No 1):S3-11, 2005
16. Formiguera X, Canton A: Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 18:1125-1146, 2004
17. Baker S, Barlow S, Cochran W, Fuchs G, Klish W, Krebs N, Strauss R, Tershakovec A, Udall J: Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 40:533-543, 2005
18. Weiss R, Caprio S: The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 19:405-419, 2005
19. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 36:594-599, 2000
20. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR: Hypertension control: how well are we doing? Arch Intern Med 163:2705-2711, 2003
21. Alexander M, Tekawa I, Hunkeler E, Fireman B, Rowell R, Selby JV, Massie BM, Cooper W: Evaluating hypertension control in a managed care setting. Arch Intern Med 159:2673-2677, 1999
22. Ornstein SM, Nietert PJ, Dickerson LM: Hypertension management and control in primary care: a study of 20 practices in 14 states. Pharmacotherapy 24:500-507, 2004
23. Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ: Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 44:429-434, 2004
24. Majernick TG, Zacker C, Madden NA, Belletti DA, Arcona S: Correlates of hypertension control in a primary care setting. Am J Hypertens 17:915-920, 2004
25. Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM: A state-wide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens 6:18-25, 2004
26. McRae RPJ, Liebson PR: Hypertensive crisis. Med Clin North Am 70:749-767, 1986
27. Vidt DG: Current concepts in treatment of hypertensive emergencies. Am Heart J 111:220-225, 1986
28. Bennett NM, Shea S: Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 78:636-640, 1988
29. Smith CB, Flower LW, Reinhardt CE: Control of hypertensive emergencies. Postgrad Med 89:111-116, 1911
30. Potter JF: Malignant hypertension in the elderly. Q J Med 88:641-647, 1995
31. Ault MJ, Ellrodt AG: Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med 3:10-15, 1985
32. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR, James TN: Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 46:559-565, 1980
33. Funakoshi Y, Ichiki T, Ito K, Takeshita A: Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34:118-125, 1999
34. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84:695-703, 1999
35. Lassegue B, Griendling KK: Reactive oxygen species in hypertension: an update. Am J Hypertens 17:852-860, 2004
36. Graves JW: Prevalence of blood pressure cuff sizes in a referral practice of 430 consecutive adult hypertensives. Blood Press Monit 6:17-20, 2001
37. Linfors EW, Feussner JR, Blessing CL, Starmer CF, Neelon FA, McKee PA: Spurious hypertension in the obese patient. Effect of sphygmomanometer cuff size on prevalence of hypertension. Arch Intern Med 144:1482-1485, 1984
38. Garcia JYJ, Vidt DG: Current management of hypertensive emergencies. Drugs 34:263-278, 1987
39. Prisant LM, Carr AA, Hawkins DW: Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med 93:92-96, 1990
40. Ziegler MG: Advances in the acute therapy of hypertension. Crit Care Med 20:1630-1631, 1992
41. Varon J, Marik PE: The diagnosis and management of hypertensive crises. Chest 118:214-227, 2000
42. Hickler RB: 'Hypertensive emergency': a useful diagnostic category. Am J Public Health 78:623-624, 1988
43. Fromm RE, Varon J, Gibbs L: Congestive heart failure and pulmonary edema for the emergency physician. J Emerg Med 13:71-87, 1995
44. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC: The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17-22, 2001
45. Sibai BM: Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 103:981-991, 2004
46. Sibai BM: Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 105:402-410, 2005
47. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W: Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 105:246-254, 2005
48. Strandgaard S, Olesen J, Skinhoj E, Lassen NA: Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1:507-510, 1973
49. Bannan LT, Beevers DG, Wright N: ABC of blood pressure reduction. Emergency reduction, hypertension in pregnancy, and hypertension in the elderly. Br Med J 281:1120-1122, 1980
50. Bertel O, Marx BE, Conen D: Effects of antihypertensive treatment on cerebral perfusion. Am J Med 82:29-36, 1987
51. Reed WG, Anderson RJ: Effects of rapid blood pressure reduction on cerebral blood flow. Am Heart J 111:226-228, 1986
52. Gifford RW Jr: Management of hypertensive crises. JAMA 266:829-835, 1991
53. Cohn LH: Aortic dissection: new aspects of diagnosis and treatment. Hosp Pract (Off Ed) 29:47-56, 1994
54. Nordlander M, Bjorkman JA, Regard H CG, Thalen P: Pharmacokinetics and hemodynamic effects of an ultrashort-acting calcium antagonist. Br J Anaesth 76(Suppl.):A24, 1996
55. Segawa D, Sjoquist PO, Wang QD, Gonon A, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts. Part II. J Cardiovasc Pharmacol 40:339-345, 2002
56. Segawa D, Sjoquist PO, Wang QD, Gonon A, Nordlander M, Ryden L: Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine. J Cardiovasc Pharmacol 36:338-343, 2000
57. Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens 24:301-313, 2002
58. Powroznyk AV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgard A, Latimer RD, Nordlander M, Feneck RO: Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 20:697-703, 2003
59. Kieler-Jensen N, Jolin-Mellgard A, Nordlander M, Ricksten SE: Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 44:186-193, 2000
60. Hirschl MM, Binder M, Bur A, Herkner H, Brunner M, Mullner M, Sterz F, Laggner AN: Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 155:2217-2223, 1995
61. DiPette DJ, Ferraro JC, Evans RR, Martin M: Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther 38:199-204, 1985
62. Hirschl MM, Binder M, Bur A, Herkner H, Woisetschlager C, Bieglmayer C, Laggner AN: Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises. J Hum Hypertens 11:177-183, 1997
63. Gay GR, Loper KA: The use of labetalol in the management of cocaine crisis. Ann Emerg Med 17:282-283, 1988
64. Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A: Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 56:14F-18F, 1985
65. Reynolds RD, Gorczynski RJ, Quon CY: Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 26(Suppl. A):A3-A14, 1986
66. Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, Tomaselli GF, Dorman T, Campbell K, Lipsett P, Breslow MJ, Rosenfeld BA: Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiol 89:1052-1059, 1998
67. Platia EV, Michelson EL, Porterfield JK, Das G: Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 63:925-929, 1989
68. Murphy MB, Murray C, Shorten GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548-1557, 2001
69. Bodmann KF, Troster S, Clemens R, Schuster HP: Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Investig 72:60-64, 1993
70. Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM, Emmanuel G, Weed SG, Panacek EA, Green JA: Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med 18:502-504, 1990
71. White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM: Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol 11:1118-1123, 1988
72. Tumlin JA, Dunbar LM, Oparil S, Buckalew V, Ram CV, Mathur V, Ellis D, McGuire D, Fellmann J, Luther RR: Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 7:653-662, 2000
73. Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 95:161-168, 1993
74. Elliott WJ, Weber RR, Nelson KS, Oliner CM, Fumo MT, Gretler DD, McCray GR, Murphy MB: Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 81:970-977, 1990
75. White WB, Halley SE: Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 149:870-874, 1989
76. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM: Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 15:I59-I62, 1990
77. Lund-Johansen P: Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs 28(Suppl. 2):35-50, 1984
78. Kanot J, Allonen H, Kleimola T, Mantyla R: Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 19:41-44, 1981
79. Pearce CJ, Wallin JD: Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med 61:59-69, 1994
80. Wallin JD: Adrenoreceptors and renal function. J Clin Hyperten 1:171-178, 1985
81. Marx PG, Reid DS: Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 8:233S-238S, 1979
82. Olsen KS, Svendsen LB, Larsen FS, Paulson OB: Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 75:51-54, 1995
83. Goldberg ME, Clark S, Joseph J, Moritz H, Maguire D, Seltzer JL, Turlapaty P: Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J 119:446-450, 1990
84. Schillinger D: Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med 5:463-473, 1987
85. Clifton GG, Cook ME, Bienvenu GS, Wallin JD: Intravenous nicardipine in severe systemic hypertension. Am J Cardiol 64:16H-18H, 1989
86. Clifton GG, Wallin JD: Intravenous nicardipine: an effective new agent for the treatment of severe hypertension. Angiology 41:1005-1009, 1990
87. Halpern NA, Sladen RN, Goldberg JS, Neely C, Wood M, Alicea M, Krakoff LR, Greenstein R: Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit Care Med 18:950-955, 1990
88. Neutel JM, Smith DH, Walllin D, Cook E, Ram CV, Fletcher E, Maher KE, Turlepaty P, Grandy S, Lee R: A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens 7:623-628, 1994
89. Yang HJ, Kim JG, Lim YS, Ryoo E, Hyun SY, Lee G: Nicardipine versus nitroprusside infusion as antihypertensive therapy in hypertensive emergencies. J Int Med Res 32:118-123, 2004
90. Lambert CR, Hill JA, Feldman RL, Pepine CJ: Effects of nicardipine on exercise- and pacing-induced myocardial ischemia in angina pectoris. Am J Cardiol 60:471-476, 1987
91. Lambert CR, Hill JA, Nichols WW, Feldman RL, Pepine CJ: Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 55:652-656, 1985
92. Vincent JL, Berlot G, Preiser JC, Engelman E, Dereume JP, Khan RJ: Intravenous nicardipine in the treatment of postoperative arterial hypertension. J Cardiothorac Vasc Anesth 11:160-164, 1997
93. Lambert CR, Hill JA, Feldman RL, Pepine CJ: Effects of nicardipine on left ventricular function and energetics in man. Int J Cardiol 10:237-250, 1986
94. van Harten J, Burggraaf K, Danhof M, van Brummelen P, Breimer DD: Negligible sublingual absorption of nifedipine. Lancet 2:1363-1365, 1987
95. Huysmans FT, Sluiter HE, Thien TA, Koene RA: Acute treatment of hypertenisve crisis with nifedipine. Br J Clin Pharmacol 16:725-727, 1983
96. Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 276:1328-1331, 1996
97. Woodmansey P, Channer KS: Nifedipine and hypotension [letter]. Lancet 338:763-764, 1991
98. Hartmann A, Buttinger C, Rommel T, Czernicki Z, Trtinjiak F: Alteration of intracranial pressure, cerebral blood flow, autoregulation and carbondioxide-reactivity by hypotensive agents in baboons with intracranial hypertension. Neurochirurgia 32:37-43, 1989
99. Kondo T, Brock M, Bach H: Effect of intra-arterial sodium nitroprusside on intracranial pressure and cerebral autoregulation. Jpn Heart J 25:231-237, 1984
100. Griswold WR, Reznik V, Mendoza SA: Nitroprusside-induced intracranial hypertension [letter]. JAMA 246:2679-2680, 1981
101. Anile C, Zanghi F, Bracali A, Maira G, Rossi GF: Sodium nitroprusside and intracranial pressure. Acta Neurochir 58:203-211, 1981
102. Mann T, Cohn PF, Holman LB, Green LH, Markis JE, Phillips DA: Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 57:732-738, 1978
103. Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H: Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306:1129-1135, 1982
104. Pasch T, Schulz V, Hoppenshauser G: Nitroprusside-induced formation of cyanide and its detoxication with thiosulphate during deliberate hypotension. J Cardiovasc Pharmacol 5:77-85, 1983
105. Hall VA, Guest JM: Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulphate prophylaxis. Am J Crit Care 2:19-27, 1992
106. Robin ED, McCauley R: Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions. Chest 102:1842-1845, 1992
107. Vesey CJ, Cole PV, Simpson PJ: Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man. Br J Anaesth 48:651-659, 1976
108. Zerbe NF, Wagner BK: Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med 21:465-467, 1993
109. O'Connor B, Luntley JB: Acute dissection of the thoracic aorta. Esmolol is safer than and as effective as labetalol [letter;comment]. BMJ 310:875, 1995
110. Hoshino T, Ohmae M, Sakai A: Spontaneous resolution of a dissection of the descending aorta after medical treatment with a beta blocker and a calcium antagonist. Br Heart J 58:82-84, 1987
111. Iguchi A, Tabayashi K: Outcome of medically treated Stanford type B aortic dissection. Jpn Circ J 62:102-105, 1998
112. Pitt MP, Bonser RS: The natural history of thoracic aortic aneurysm disease: an overview. J Cardiac Surg 12:270-278, 1997
113. Borst HG, Laas J: Surgical treatment of thoracic aortic aneurysms. Adv Cardiac Surg 4:47-87, 1993
114. Chen K, Varon J, Wenker OC, Judge DK, Fromm RE, Sternbach GL: Acute thoracic aortic dissection: the basics. J Emerg Med 15:859-867, 1997
115. Wallace JD, Levy LL: Blood pressure after stroke. JAMA 246:2177-2180, 1981
116. Lavin P: Management of hypertension in patients with acute stroke. Arch Intern Med 146:66-68, 1986
117. O'Connell J, Gray C: Treating hypertension after stroke. Br Med J 308:1523-1524, 1994
118. Emergency Cardiac Care Committee and Subcommittees, American Heart Association: Guidelines for Cardiopulmonary resuscitation and emergency cardiac care. Part IV. Special resuscitation situations: stroke. JAMA 268:2242-2244, 1992
119. Adams HP Jr, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA: Guidelines for the management of patients with acute ischemic stroke. A statement for the healthcare professionals from a special writing group of the stroke council, American Hear Association. Circulation 90:1588-1601, 1994
120. O'Connell JE, Gray CS: Treatment of post-stroke hypertension. A practical guide. Drugs Aging 8:408-415, 1996
121. Semplicini A, Maresca A, Boscolo G, Sartori M, Rocchi R, Giantin V, Forte PL, Pessina AC: Hypertension in acute ischemic stroke: a compensatory mechanism or an additional damaging factor? Arch Intern Med 163:211-216, 2003
122. Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, Buonanno FS: A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology 56:1210-1213, 2001
123. Hirschl MM: Guidelines for the drug treatment of hypertensive crises. Drugs 50:991-1000, 1995
124. Qureshi AI, Bliwise DL, Bliwise NG, Akbar MS, Uzen G, Frankel MR: Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med 27:480-485, 1999
125. Belfort MA, Anthony J, Saade GR, Allen JC Jr, Nimodipine Study Group: A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 348:304-311, 2003
126. Coetzee EJ, Dommisse J, Anthony J: A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 105:300-303, 1998
127. Lucas MJ, Leveno KJ, Cunningham FG: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 333:201-205, 1995
128. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: Report of the National High Blood Pressure Education Program Working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1-S22, 2000
129. American College of Obstetricians and Gynecologists: Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. Obstet Gynecol 99:159-167, 2002
130. Cunningham FG: Severe preeclampsia and eclampsia: systolic hypertension is also important. Obstet Gynecol 105:237-238, 2005
131. Hellman LM, Pritchard JA: Williams Obstetrics, 14th edn. New York: Appleton-Century-Crofts, 1971
132. Magee LA, Cham C, Waterman EJ, Ohlsson A, von DP: Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327:955-960, 2003
133. Pickles CJ, Broughton PF, Symonds EM: A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol 99:964-968, 1992
134. Pickles CJ, Symonds EM, Pipkin FB: The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol 96:38-43, 1989
135. Mabie WC, Gonzalez AR, Sibai BM, Amon E: A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 70:328-333, 1987
136. Jannet D, Carbonne B, Sebban E, Milliez J: Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol 84:354-359, 1994
137. Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J: Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 81:908-914, 1993
138. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD: Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 112:897-903, 1990
139. Pitts WR, Lange RA, Cigarroa JE, Hillis LD: Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis 40:65-76, 1997
140. Hollander JE: The management of cocaine-associated myocardial ischemia. N Engl J Med 333:1267-1272, 1995
141. Dusenberry SJ, Hicks MJ, Mariani PJ: Labetalol treatment of cocaine toxicity [letter]. Ann Emerg Med 16:235, 1987
142. Spivey WH, Schoffstall JM, Kirkpatrick R, Fuhs L: Comparison of labetalol, diazepam, and haloperidol for the treatment of cocaine toxicity in a swine mode [Abstract]. Ann Emerg Med 19:467-468, 1990
143. Catravas JD, Waters IW: Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther 217:350-356, 1981
144. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA: Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 94:608-610, 1993
145. Negus BH, Willard JE, Hillis LD, Glamann DB, Landau C, Snyder RW, Lange RA: Alleviation of cocaine-induced coronary vasoconstriction with intravenous verapamil. Am J Cardiol 73:510-513, 1994
146. Moore NA, Rees G, Sanger G, Awere S: Effect of l-type calcium channel modulators on stimulant-induced hyperactivity. Neuropharmacology 32:719-720, 1993
147. Hollander JE, Carter WA, Hoffman RS: Use of phentolamine for cocaine-induced myocardial ischemia [Letter]. N Engl J Med 327:361, 1992